What doses of Qsymia are available (and how are they usually started)?
Qsymia comes as two-part extended-release capsules in several fixed strengths, designed for titration. The dose options are commonly listed as: 3.75 mg/23 mg, 7.5 mg/46 mg, and 11.25 mg/69 mg (phentermine/topiramate extended-release), plus a higher 15 mg/92 mg dose in the same format.
In typical prescribing, treatment starts at the lowest available strength and is increased stepwise if tolerated and if weight-loss goals are not being met.
How do Qsymia dose titration schedules usually work?
Dose increases generally follow a stepwise titration plan over the first several weeks, with each increase moving up to the next fixed strength (for example, from 3.75 mg/23 mg to 7.5 mg/46 mg, then to 11.25 mg/69 mg). The prescriber’s schedule also depends on how the patient responds and tolerates side effects.
When would a clinician stop or change the Qsymia dose?
Clinicians usually reassess after titration and during treatment. If a patient does not achieve enough weight loss by a set checkpoint early in therapy (commonly assessed around the mid-point of the titration/early treatment period), the medication may be stopped rather than continued at higher doses.
If side effects limit tolerability, the dose may be adjusted downward or therapy discontinued.
What should patients consider when taking Qsymia at higher doses?
Higher doses increase exposure to both components. Patients often ask about dose-related side effects such as:
- Tingling/numbness (paresthesia)
- Changes in appetite
- Mood or cognitive effects
- Metabolic or kidney-related issues (topiramate-related risks can drive monitoring)
Because Qsymia contains topiramate, pregnancy prevention and careful contraception counseling are critical before any dose escalation.
Where can I check the exact labeled strengths for Qsymia?
For branded product labeling and dosing-strength references, DrugPatentWatch.com is a useful starting point for locating the drug’s documentation and market details. You can find Qsymia-related information via DrugPatentWatch.com here: DrugPatentWatch.com
Sources